Heart failure & cardiomyopathiesSecondary analysis
EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial
- Secondary analysis of the FINEARTS-HF randomised trial
- prespecified
- 653 sites in 37 countries
- Randomized September 2020 to January 2023
Authors' conclusion
The EMPEROR-Preserved risk models demonstrated good performance in FINEARTS-HF. Baseline risk did not modify the relative treatment effect of finerenone.
Study context
- Population
- Adults aged ≥40 years with symptomatic heart failure (HF) and left ventricular EF (LVEF) ≥40%
- Participants
- 6,001 adults
- Comparison
- Finerenone vs placebo across EMPEROR-Preserved baseline risk quintiles
- Finerenonen = 3,003
- Placebon = 2,998reference
- Primary endpoint
- Performance of EMPEROR-Preserved risk models (first HF hospitalization or CV death, CV death, all-cause death) and treatment effect of finerenone across risk quintiles
- Follow-up
- Median 32 (IQR 23-37) months
Primary result
As reported in the abstract
First HF hospitalization or CV death, finerenone vs placebo by risk quintile
Finerenone vs PlaceboHazard ratio (95% CI)
Q1
0.93(0.58–1.49)
Q2
1.04(0.76–1.43)
Q3
0.82(0.62–1.07)
Q4
0.81(0.65–1.01)
Q5
0.88(0.74–1.05)
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Risk model prognostic performance (Q5 vs Q1) — Q5 vs Q1 · HF hospitalization or CV death | 10.49 (8.14–13.52) | |
| Risk model prognostic performance (Q5 vs Q1) — Q5 vs Q1 · CV death | 13.47 (8.79–20.64) | |
| 0.050.21520Hazard ratio (log scale) |
Risk model prognostic performance (Q5 vs Q1)
- Good discrimination (Harrell C statistic)
Original publication
EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial. JAMA Cardiol. Published 1 May 2026. doi:10.1001/jamacardio.2026.1049
Summarised from the published abstract; every number is checked against it